New Data Shows Eversense 365 CGM Delivers Sustained Performance Over One Year

Real-world evidence presented at ATTD demonstrates strong patient adherence, glucometrics, and hypoglycemic outcomes with Senseonics' one-year implantable CGM system.

Mar. 14, 2026 at 3:38pm

Got story updates? Submit your updates here. ›

Senseonics, a medical technology company, has presented new real-world data on the performance of its Eversense 365 continuous glucose monitoring (CGM) system at the ATTD conference. The analysis of the first 5,059 Eversense 365 sensors used by patients in the US showed strong patient adherence, with an average transmitter wear time of 93.8%, and positive glycemic outcomes, including a mean Glucose Management Indicator (GMI) of 7.14% and a mean Time in Range (TIR) of 66%. The data also indicated that over 75% of users achieved hypoglycemic targets, highlighting the accuracy of Eversense 365 in low glucose ranges.

Why it matters

The real-world evidence presented on Eversense 365 demonstrates the potential of this long-term, implantable CGM system to transform diabetes management. By providing a full year of consistent and accurate glucose monitoring with minimal interruptions, Eversense 365 can help patients better control their diabetes and reduce the burden of frequent sensor changes associated with traditional CGM systems. The data also suggest that Eversense 365 may provide particular benefits for older adults and young adults, two populations that often struggle with glycemic control.

The details

The study evaluated the first 5,059 real-world Eversense 365 CGM sensors used by patients in the US with open-loop insulin regimens. The analysis revealed strong patient adherence, with an average transmitter wear time of 93.8% and comparable results for the first and second six-month periods, indicating consistent and meaningful system use. This resulted in a mean Glucose Management Indicator (GMI) of 7.14% and a mean Time in Range (TIR) of 66%, demonstrating effective glycemic control. Furthermore, over 75% of users achieved hypoglycemic targets, reinforcing the accuracy of Eversense 365 in low glucose ranges.

  • Eversense 365 was approved by the FDA in September 2024 and launched in the US in October 2024.
  • Eversense 365 received European CE Mark approval in January 2026, and Senseonics expects to launch the system in Germany, Italy, Spain, and Sweden in the coming months.

The players

Senseonics

A medical technology company focused on the development, manufacturing, and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes.

Francine Kaufman, M.D.

Chief Medical Officer at Senseonics.

Brian Hansen

Chief Commercial Officer at Senseonics.

Got photos? Submit your photos here. ›

What they’re saying

“The promise of a year-long CGM has now been demonstrated in the real world.”

— Francine Kaufman, M.D., Chief Medical Officer at Senseonics

“We are proud to present these data at ATTD, which is always a fantastic opportunity to connect with the diabetes ecosystem and discuss the latest developments in technology and care.”

— Brian Hansen, Chief Commercial Officer at Senseonics

What’s next

Senseonics plans to present a longer-term real-world analysis of the twiist Automated Insulin Delivery (AID) system combined with Eversense 365 later this year.

The takeaway

The real-world evidence on Eversense 365 demonstrates the potential of this long-term, implantable CGM system to transform diabetes management by providing a full year of consistent and accurate glucose monitoring with minimal interruptions, helping patients better control their diabetes and reduce the burden of frequent sensor changes associated with traditional CGM systems.